Palvella Therapeutics (PVLA) Cash from Investing Activities (2014 - 2026)

Palvella Therapeutics (PVLA) has reported Cash from Investing Activities for 12 consecutive years, with -$55.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$55.4 million; the TTM figure through Mar 2026 stood at -$53.1 million (down 569.36% YoY), while the FY2023 annual figure was $12.0 million, up 156.52% from the prior year.
• Cash from Investing Activities fell to -$55.4 million in Q1 2026 per PVLA's latest filing, from $142000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $11.9 million in Q1 2023 and bottomed at -$55.4 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$4.4 million across 4 years, with a median of $624500.0 in 2022.
• On a YoY basis, Cash from Investing Activities climbed as much as 1662.86% in 2022 and fell as far as 60428.57% in 2022.
• Palvella Therapeutics' Cash from Investing Activities stood at $1.1 million in 2022, then jumped by 211.56% to $3.4 million in 2023, then sank by 95.88% to $142000.0 in 2024, then sank by 39142.25% to -$55.4 million in 2026.
• Business Quant data shows PVLA's Cash from Investing Activities at -$55.4 million in Q1 2026, $142000.0 in Q3 2024, and $2.2 million in Q2 2024.